Major Strides in HER2 Blockade for Metastatic Breast Cancer

被引：8
|
作者：
Sharma, Priyanka [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 07期
关键词：
TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; SURVIVAL;
D O I：
10.1056/NEJMe1916310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Breast cancer that is characterized by amplification or overexpression of human epidermal growth factor receptor 2 (HER2) accounts for 15 to 20% of all forms of the disease. The advent of HER2-targeted drugs, such as trastuzumab, pertuzumab, lapatinib, and the antibody-drug conjugate trastuzumab emtansine, has revolutionized the treatment of both early-stage and metastatic HER2-positive breast cancer.(1-4) The increasing availability of HER2-targeted agents has led to improved outcomes for patients with HER2-positive metastatic breast cancer, as reported in a study in which overall survival rose from a median of 38.7 months to 51.1 months from 2008 through 2012.(5) The standard first-line . . .
引用
收藏
页码：669 / 671
页数：3
相关论文
共 50 条
  • [1] Dual HER2 Blockade Slows Metastatic Breast Cancer
    Bender, Eric
    CANCER DISCOVERY, 2012, 2 (01)
  • [2] Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer
    Bidard, F. -C.
    Ng, C. K. Y.
    Cottu, P.
    Piscuoglio, S.
    Escalup, L.
    Sakr, R. A.
    Reyal, F.
    Mariani, P.
    Lim, R.
    Wang, L.
    Norton, L.
    Servois, V.
    Sigal, B.
    Vincent-Salomon, A.
    Weigelt, B.
    Pierga, J. -Y.
    Reis-Filho, J. S.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1704 - 1709
  • [3] Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer
    Van Raemdonck, E.
    Berteloot, P.
    Laenen, A.
    Han, S.
    Van Nieuwenhuysen, E.
    Salihi, R.
    Concin, N.
    Vergote, I.
    Floris, G.
    Wildiers, H.
    Punie, K.
    Neven, P.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [5] Somatic mutations of the HER2 in metastatic breast cancer
    Fang, Yi
    Jiang, Yanxia
    Wang, Xin
    Yang, Xue
    Gao, Yinqi
    Wang, Jing
    TUMOR BIOLOGY, 2014, 35 (12) : 11851 - 11854
  • [6] Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab in HER2 positive metastatic or locally recurrent unresectable breast cancer: assessment of toxicity
    Ajgal, Z.
    De Percin, S.
    Loirat, D.
    Pierga, J. Y.
    Campana, F.
    Fourquet, A.
    Kirova, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S50 - S51
  • [7] Dual HER2 inhibition and paclitaxel in metastatic breast cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2015, 16 (02): : E57 - E57
  • [8] HER2 overexpression in metastatic breast cancer: development of therapies
    Pivot, X.
    Jary, M.
    Dobi, E.
    Bazan, F.
    Chaigneau, L.
    Cals, L.
    Almotlak, H.
    Montcuquet, P.
    Meneveau, N.
    Villanueva, C.
    ONCOLOGIE, 2012, 14 (01) : 37 - 40
  • [9] Precision medicine for HER2 negative metastatic breast cancer
    Hara, Fumikata
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Proliferation Index in "HER2 Low" Metastatic Breast Cancer
    Hrizat, A. S.
    Brachtel, E.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 : S13 - S14
12345